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Because of their useful chemical and physical properties, nanomaterials are widely used around the world - for
example, as additives in food and medicines - and such uses are expected to become more prevalent in the future.
Therefore, collecting information about the effects of nanomaterials on metabolic enzymes is important. Here, we
examined the effects of amorphous silica particles with various sizes and surface modifications on cytochrome P450
3A4 (CYP3A4) activity by means of two different in vitro assays. Silica nanoparticles with diameters of 30 and 70 nm
(nSP30 and nSP70, respectively) tended to inhibit CYP3A4 activity in human liver microsomes (HLMs), but the inhibitory
activity of both types of nanoparticles was decreased by carboxyl modification. In contrast, amine-modified nSP70
activated CYP3A4 activity. In HepG2 cells, nSP30 inhibited CYP3A4 activity more strongly than the larger silica particles
did. Taken together, these results suggest that the size and surface characteristics of the silica particles determined their
effects on CYP3A4 activity and that it may be possible to develop silica particles that do not have undesirable effects
on metabolic enzymes by altering their size and surface characteristics.
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The small size and high surface area of nanomaterials
(which are defined as materials with at least one external
dimension in the size range of 1 to 100 nm) give them
useful properties such as unique chemical reactivity, heat
conductivity, and ability to permeate tissues. Therefore,
nanomaterials are expected to be used for applications
in many fields [1,2]. In particular, amorphous silica
nanoparticles are among the most widely used nanoma-
terials because of their comparatively low cost, their
straightforward synthesis, and the ease with which their
surfaces can be modified [3]. Silica nanoparticles are
already widely used in cosmetics, food, and medicines
[4-6]. Therefore, collecting information about the safety* Correspondence: yasuo@phs.osaka-u.ac.jp; ytsutsumi@phs.osaka-u.ac.jp
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in any medium, provided the original work is pof silica nanoparticles is important [7,8]. In previous
work, we found that they can penetrate the skin and
enter various tissues [9] and that at high doses, they are
more likely to induce consumptive coagulopathy and
liver damage than do silica microparticles [10].
Because silica nanoparticles are used in food and drugs,
their effects on metabolic enzymes such as cytochrome
P450s (CYPs) are of particular interest. Xenobiotics such
as drugs are metabolized by CYPs which are expressed at
the highest levels in the liver. Cytochrome P450 3A4
(CYP3A4) is the most abundant CYP isozyme expressed
in human liver tissue and is involved in the metabolism of
approximately half of the drugs in use [11,12]. Drugs,
some foods and beverages, and various chemicals such as
those in cigarette affect the activity of CYPs. For example,
ketoconazole, cyclosporine A, ritonavir, and grapefruit
juice inhibit CYP3A4 activity and thus can lead to side
effects when taken with drugs metabolized by CYP3A4
[13,14]. In contrast, rifampicin and St. John’s wort induce
CYP3A4 and thus reduce the efficacy of some drugs
that undergo CYP3A4-dependent metabolism [13,15].Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Imai et al. Nanoscale Research Letters 2014, 9:651 Page 2 of 7
http://www.nanoscalereslett.com/content/9/1/651Nanomaterials have also been reported to affect CYP3A4
activity. For example, nonmetallic carboxyl polystyrene
nanoparticles (20 nm) inhibit the activity of CYP3A4
in microsomes isolated from baculovirus-infected cells
expressing wild-type CYP3A4 [16], and silver nano-
particles dose-dependently decrease the amount of 6β-
hydroxytestosterone, which is generated mainly by CYP3A4,
in human liver microsomes (HLMs) [17].
Considering that silica nanoparticles are already used
in foods and medicines, their effects on CYPs must be
thoroughly explored. Silica nanoparticles are reported to
be distributed to the liver after dermal, oral, intranasal,
and intravenous administration [9,18,19]. In addition, we
previously demonstrated that 70-nm silica nanoparticles
are localized in the cytoplasm, which contains many
enzymes related to metabolism such as CYPs [9]; there-
fore, silica nanoparticles have the opportunity to react
with CYPs. Furthermore, Nishimori et al. and Li et al.
showed that when administered to mice together, 70-nm
silica nanoparticles and some drugs increased the tox-
icity on the liver relative to that observed when either is
administered alone in mice [20,21]. These results suggest
that silica nanoparticles may affect the activity of CYPs,
but these potential effects have not been evaluated. In
addition, little information is available about the effects
of the size and surface characteristics of nanomaterials
on CYP3A4 activity. In this study, we examined CYP3A4
activity in human hepatocellular carcinoma cells (HepG2)




Silica nanoparticles with diameters of 30 and 70 nm
(nSP30 and nSP70, respectively), conventional silica micro-
particles with diameters of 300 and 1,000 nm (mSP300 and
mSP1000, respectively), and nSP30 and nSP70 modified
with carboxyl groups (nSP30-C and nSP70-C, respectively)
or amine groups (nSP30-N and nSP70-N, respectively)
were purchased from Micromod Partikeltechnologie
GmbH (Friedrich-Barnewitz, Rostock, Germany). The silica
particles were suspended in water, and the suspensions
were stored at room temperature. Immediately prior to use,
they were sonicated for 5 min and then vortexed for 1 min.
Physicochemical examination of the silica preparations
Silica particles were diluted to 0.1 or 0.2 mg/mL with
ultrapure water or Dulbecco’s modified Eagle’s medium
(Wako Pure Chemical Industries, Osaka, Japan) supple-
mented with 10% fetal calf serum (FCS) and 1% antibiotic-
antimycotic mix stock solution (Ab) (Gibco, Carlsbad,
CA, USA), and the average particle size and surface charge
(zeta potential) were determined using a Zetasizer Nano-
ZS (Malvern Instruments Ltd., Malvern, UK). The size ofsilica particles were measured by dynamic light scattering.
The surface charge was measured by laser Doppler
electrophoresis.
Reagents
Pooled HLMs (Xtreme 200) were obtained from XenoTech
(Lenexa, KS, USA). Ketoconazole, a representative CYP3A4
inhibitor, was obtained from Wako Pure Chemical Indus-
tries (Osaka, Japan). Luciferin-isopropyl acetal (LIPA;
Promega, Madison, WI, USA), which is metabolized spe-
cifically by CYP3A4 and releases luciferin, was used as a
probe substrate to quantify CYP3A4 activity by lumines-
cence after the reaction of LIPA with an ATP-luciferase
reaction mixture [22].
Evaluation of CYP3A4 activity in HLMs
The inhibitory effects of silica particles at various concen-
trations (2, 10, 50, 200, and 800 μg/mL) and ketoconazole
(200 nmol/L) were determined with HLMs (20 μg/mL) in
the presence of NADPH Regenerating System (Promega).
The incubation mixtures, which consisted of silica
particles, ketoconazole, 10 μmol/L LIPA, and HLMs in
potassium phosphate buffer (15 μL, respectively), were
pre-incubated for 10 min at 37°C, and then the enzymatic
reactions were initiated by the addition of 15 μL of
NADPH. In addition, to determine whether LIPA was
physically bound to the silica particles, we also started
the reaction by adding 15 μL of LIPA after preparing a
mixture of the silica particles, HLMs, buffer, and NADPH.
Next, to determine whether the silica particles were
physically bound to microsome proteins, we centrifuged a
mixture of silica particles, LIPA, HLMs, and buffer at
1,000 × g or 5,000 × g for 20 min and then added NADPH
(15 μL) to the supernatant (45 μL). For each of these
procedures, the reactions were terminated after 10 min
of incubation by the addition of reconstitution buffer
(60 μL). Each plate was incubated at room temperature
for 20 min, and then the luminescence was read with a
luminometer for 1 s per well.
Cell culture
HepG2 cells were maintained in Dulbecco’s modified
Eagle’s medium including 10% FCS and 1% Ab.
Lactate dehydrogenase release assay in HepG2 cells
The lactate dehydrogenase (LDH) activity in HepG2 cells
exposed to silica particles was determined with a com-
mercial LDH cytotoxicity test (Wako Pure Chemical
Industries) conducted according to the manufacturer’s
instructions. In brief, HepG2 cells (1 × 105 cells/well) were
pre-cultured in 24-well plates for 24 h, the pre-culture
medium was removed, and the cells were incubated with
silica particles (25 to 200 μg/mL) for 48 h. Then, 50 μL of
the supernatant was used for LDH analysis. Absorbance at
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percentage of cellular survival was calculated by means of
the following equation:
Cellular survival %ð Þ ¼ 100 − 100 A–Bð Þ= C – Bð Þ½ 
where A is the absorbance measured for a well treated
with silica particles, B is the absorbance measured for an
untreated well, and C is the absorbance measured for a
well treated with 0.1% Triton X.
Evaluation of CYP3A4 activity in HepG2 cells
HepG2 cells were treated with silica particles by means
of the protocol described for the LDH release assay.
After a 48-h incubation period, the incubation medium was
aspirated, the cells were washed twice with phosphate-
buffered saline, and 200 μL of LIPA (3 μmol/L) was added
to each well. After 1 h, a 100-μL aliquot of culture medium
including LIPA was transferred from each well to a 96-well
opaque white luminometer plate at room temperature, and
then 100 μL of Luciferin Detection Reagent was added to
initiate the luminescence reaction. The plate was incubated
at room temperature for 20 min, and then the lumines-
cence was read for 1 s with a luminometer.
Statistical analysis
All data are presented as mean ± SD. Differences were
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Figure 1 Effect of silica particles on CYP3A4 activity in HLMs. (A) Silica
was measured, and the percentage of CYP3A4 activity was calculated relati
mean ± SD for three independent determinations. **P < 0.01 and *P < 0.05
of CYP3A4 activity in HLMs by silica particles.experimental groups and the control group were consid-
ered significant at P < 0.05.
Results and discussion
To evaluate the effect of silica particles on CYP3A4
activity, we measured CYP3A4 activity of HLMs and
HepG2 cells after treating with silica particles. To eluci-
date the influence of size and surface modification of sil-
ica nanoparticles on their effect for CYP3A4 activity, we
used silica particles with various sizes and surface
modifications.
Physicochemical properties of silica particles
First, the particle size and surface charge of silica particles
in water and medium were measured. The particle size
and surface charge of several particles used in this study
were reported in previous studies [9,23-26]. However, we
measured these parameters again. Mean particle sizes of
nSP30, nSP30-C, nSP30-N, nSP70, nSP70-C, nSP70-N,
mSP300, and mSP1000 measured by dynamic light
scattering method were 36.8 ± 0.3, 49.0 ± 1.7, 40.4 ± 0.9,
86.2 ± 2.7, 78.7 ± 0.3, 103 ± 0, 293.0 ± 2.7, and 1,253.3 ±
32.1 nm (in water), respectively, and 84.9 ± 1.9, 294.0 ±
45.0, 410.3 ± 48.2, 128.3 ± 2.3, 267.0 ± 28.6, 267.3 ± 2.1,
249.3 ± 24.0, and 1,083.3 ± 35.1 nm (in medium), respect-
ively. The surface charge of nSP30, nSP30-C, nSP30-N,
nSP70, nSP70-C, nSP70-N, mSP300, and mSP1000 mea-
sured by laser Doppler electrophoresis was −32.5 ±















0 nSP70-C nSP70-N mSP300 mSP1000
>800 >800 190 >800
particles were incubated with HLMs for 10 min. Then, CYP3A4 activity
ve to the activity of sterile water as a control. Data are presented as
versus the control group (Dunnett’s test). (B) IC50 values for inhibition
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ively, and −9.0 ± 1.0, −11.2 ± 0.2, −11.1 ± 1.1, −10.0 ±
0.1, −10.2 ± 0.5, −10.1 ± 1.0, −9.3 ± 0.5, and −10.0 ±
1.6 mV (in medium), respectively.
Effects of silica particles on CYP3A4 activity in HLMs
Silica particles at concentrations of 2, 10, 50, 200, and
800 μg/mL were incubated with HLMs, and inhibition
constants (IC50) were determined (Figure 1). The activity of
CYP3A4 decreased dose-dependently upon co-incubation
with nSP30, nSP30-C, nSP30-N, nSP70, nSP70-C, or
mSP300. In contrast, we observed no significant differ-
ence in the CYP3A4 activity of the mSP1000-treated
group compared to that of the control group. For the
unmodified silica particles, IC50 increased with increasing
particle size. This result suggests that smaller silica parti-
cles have a greater potential to suppress CYP3A4 activity.
In contrast, the IC50 values for nSP30 and nSP70 were
lower than the values for nSP30-C, nSP30-N, and nSP70-
C, indicating that surface modification changed the inhibi-
tory potential of the particles. Surprisingly, we found that
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Figure 2 Evaluation of the interaction between silica particles and a pro
(200 nmol/L) was incubated with HLMs, and CYP3A4 activity was then measur
of NADPH after pre-incubation of the silica particles with the probe substrate, o
substrate after pre-incubation of the silica particles with NADPH. (B) Mixtures o
1,000 × g or 5,000 × g for 20 min, or the mixtures were not centrifuged. The CY
CYP3A4 activity was calculated relative to the activity of sterile water as a controincreased CYP3A4 activity. Note, however, that differ-
ences in the size of nanomaterials reportedly affect their
protein-binding mode [27]. Therefore, nSP30-N, which
also has amino groups but did not activate CYP3A4, may
interact with CYP3A4 differently than nSP70-N does.
Next, we investigated the mechanism of the effects of
silica nanoparticles on CYP3A4 activity. First, we consid-
ered the possibility that the silica particles bound to the
substrate and prevented interaction of the substrate and
the enzyme (Figure 2A). We compared CYP3A4 activity
under the following two conditions: (1) the enzymatic
reaction was started by the addition of NADPH, which
causes microsomal oxidation, after pre-incubation of the
silica particles with a probe substrate, and (2) the en-
zymatic reaction was started by the addition of the probe
substrate after pre-incubation of the silica particles with
NADPH. Instead of silica particles, we also used ketocona-
zole which suppresses CYP3A4 activity without affecting
the substrate. For all the silica particles and ketoconazole,
the CYP3A4 activity was almost exactly the same under
the two conditions, indicating that the silica particles did
not affect the substrate-enzyme interaction.KetoconazoleP70-C nSP70-N mSP300 mSP1000
KetoconazoleP70-C nSP70-N mSP300 mSP1000
be substrate or CYP3A4. (A) Silica particles (200 μg/mL) or ketoconazole
ed in two ways: (1) the enzymatic reaction was started by the addition
r (2) the enzymatic reaction was started by the addition of the probe
f microsomes, the probe substrate, and silica particles were centrifuged at
P3A4 activity of each supernatant was measured, and the percentage of
l. Data are presented as mean ± SD for three independent determinations.
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bound to microsome proteins, we centrifuged mixtures of
microsomes, substrate, and silica particles and then mea-
sured the CYP3A4 activity in the supernatant (Figure 2B).
We found that the CYP3A4 activity in groups treated with
silica particles was dramatically lower in the centrifugation
group compared to the uncentrifuged control, except
in the case of the group treated with mSP1000 and
ketoconazole. Microsome proteins and ketoconazole
are not usually precipitated by centrifugation at either
1,000 × g or 5,000 × g. Therefore, these results suggest
that microsome proteins bound to the silica nanopar-
ticles and to mSP300 to form complexes that were
heavy enough to be precipitated by centrifugation at
















































Figure 3 Effect of silica particles on membrane damage and CYP3A4 ac
for 48 h. (A) An LDH release assay was conducted with the supernatant, and
HepG2 cells was measured, and CYP3A4 activity was calculated relative to tha
for three independent cultures. **P < 0.01 and *P < 0.05 versus control groupnanoparticles and mSP300 physically bound to microsome
proteins and affected the CYP3A4 activity in HLMs.
Bertoli et al. suggested the possibility that silica-coated
magnetic 50-nm nanoparticles bind to CYPs in cells [28].
Therefore, mSP300 and the silica nanoparticles (except
nSP70-N) may have bound to CYP3A4 and blocked its
substrate-binding site or may have converted CYP3A4 to
an inactive conformation, whereas nSP70-N bound to
CYP3A4 and changed it to an active conformation.
Cytotoxicity of silica particles to HepG2 cells and CYP3A4
activity in HepG2 cells
To examine the influence of silica particles on CYP3A4
activity in hepatocytes, we evaluated cellular survival
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tivity in HepG2 cells. HepG2 cells were incubated with silica particles
the percentage of surviving cells was calculated. (B) CYP3A4 activity in
t of the culture medium as a control. Data are presented as mean ± SD
(Dunnett’s test).
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survival rates in the groups treated with silica particles
at concentrations of 25, 50, 100, and 200 μg/mL were
almost 100%, indicating that none of the particles induced
membrane damage in HepG2 cells under our experimen-
tal conditions (Figure 3A). In contrast, treatment with
nSP30 at 50, 100, or 200 μg/mL, treatment with nSP30-C
at 100 or 200 μg/mL, treatment with nSP30-N at
100 μg/mL, or treatment with nSP70-C at 200 μg/mL
resulted in significantly lower CYP3A4 activity com-
pared with the activity in the control group, whereas
treatment with nSP70, nSP70-N, mSP300, or mSP1000 had
no effect on CYP3A4 activity. These results suggest that
smaller silica particles had greater potential to suppress
CYP3A4 activity in cells. We confirmed that nSP30-N were
aggregated at 200 μg/mL (mean particle size in medium,
410.3 ± 48.2 nm) compared to those at 100 μg/mL (mean
particle size in medium, 121.0 ± 15.4 nm). That may be the
reason why the treatment of nSP30-N at 200 ug/mL did
not decrease CYP3A4 activity.
Both the HepG2 assay and the HLM assay showed
similar results with regard to the relationship between
particle size and CYP3A4 inhibition activity. However,
the two assays showed slightly different results with
regard to the relationship between surface modification
and CYP3A4 activity. In HepG2 cells (Figure 3B), the
nSP70-C-treated group showed significantly inhibited
CYP3A4 activity compared to the control group at a
concentration at which nSP70 did not inhibit the activity
(200 μg/mL), and nSP30-C showed almost the same
CYP3A4 inhibition activity as nSP30. In contrast, the
HLM assay showed that nSP70 and nSP30 inhibited
CYP3A4 more strongly than did nSP70-C and nSP30-C,
respectively (Figure 1). The explanation for the differ-
ence between the unmodified silica nanoparticles and
carboxyl-modified nanoparticles remains to be determined.
However, Chung et al. showed that the surface charge of
mesoporous silica particles could mediate cellular uptake
rate or even cellular uptake route of the particles [29].
Therefore, change of surface charge by carboxyl modifica-
tion may affect silica nanoparticles’ cellular uptake. In fact,
Ekkapongpisit et al. showed that carboxyl modification
of 50-nm mesoporous silica particles changes their cel-
lular uptake [30], and we have also found that nSP70
and nSP70-C have different intracellular localizations
[25]. Thus, differences in cellular uptake or intracellular
localization between unmodified and carboxyl-modified
silica nanoparticles may explain the different results
observed in cells and under conditions where the parti-
cles have direct access to microsomes.
Conclusions
We report for the first time that silica particles can
either inhibit or activate CYP3A4 activity in vitro. Weshowed that smaller particles have a greater potential to
inhibit CYP3A4 activity than larger particles and that
surface modification of silica particles could change their
effects on CYP3A4 activity. Our results suggest that
optimization of the size and surface modification of silica
particles will contribute to the development of safer appli-
cations of silica nanoparticles.
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